Sanofi SA (SNY) Appoints New R&D Head Amid 5% Dividend Yield
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowSanofi SA (NASDAQ: SNY) announced the appointment of Paulo Fontoura as Executive Vice President and Global Head of Research & Development effective September 1. Fontoura will oversee the company's end-to-end innovation engine across multiple therapeutic areas, succeeding Dr. Houman Ashrafian. The appointment is significant as Sanofi progresses in its R&D transformation and aims to accelerate the development of new medicines. Additionally, MacroGenics confirmed it will receive $24.5 million from Sanofi due to regulatory milestone payments related to the FDA's accelerated approval of TZIELD.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
